In an attempt to develop vaccine approaches exhibiting improved anti-tumor efficacy in the subcutaneous (s.c.)B16 melanoma model, we examined combination vaccine regimens that coordinately target both intrinsic melanoma antigens and TBVAs and/or which contain treatment agents known to enhance the recruitment of T cells into tumors (i.e., chemokine-modulating regimen, CKM) [16] or to prevent exhaustion and sustain/recover the polyfunctionality of T cells (i.e., anti-PD-L1) [17,18]. The gene discussed is CD274; the disease is melanoma.